Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + prednisolone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Docetaxel + prednisolone** is a combination chemotherapy regimen primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). **Docetaxel** is a taxane-class chemotherapy agent that promotes and stabilizes microtubule assembly, disrupting mitosis and resulting in cell death. **Prednisolone** is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant; in this regimen, it helps to reduce certain chemotherapy side effects and may enhance quality of life. Mechanistically, docetaxel acts as an antineoplastic by interfering with microtubule dynamics, while prednisolone exerts glucocorticoid receptor agonism, impacting gene expression and inflammatory cytokine production. This combination improves overall survival compared to earlier regimens in prostate cancer and is a standard first-line option for mCRPC. The combination is administered intravenously (docetaxel) and orally (prednisolone), typically in 3-week cycles, with dose and duration dependent on clinical protocols.
- Other names
- docetaxel prednisolonedocetaxel plus prednisolone
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on docetaxel + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + prednisolone.